视神经脊髓炎谱系疾病免疫治疗的研究进展  

Progress of immunotherapy in neuromyelitis optica spectrum disorders

作　　者：杨春生[1] 张秋侠 张璘洁[1] 周冰洁[1] 张超[1] 杨丽[1] Yang Chunsheng;Zhang Qiuxia;Zhang Linjie;Zhou Bingjie;Zhang Chao;Yang Li(Department of Neurology,Tianjin Neurological Institute,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院神经内科,300052

出　　处：《中华全科医师杂志》2019年第5期488-491,共4页Chinese Journal of General Practitioners

基　　金：国家自然科学基金(81571172).

摘　　要：视神经脊髓炎谱系疾病(NMOSD)是一组最常累及视神经和脊髓的中枢神经系统炎性脱髓鞘疾病,具有缓解复发的特点,且复发率高、残疾重。预防复发是NMOSD治疗的关键。文章总结了预防NMOSD复发的经典的免疫抑制剂包括泼尼松、硫唑嘌呤、吗替麦考酚酯、甲氨蝶呤等及新的治疗药物如利妥昔单抗、IL-6受体抗体、伊库珠单抗等,并对新的免疫治疗进行展望。Neuromyelitis optica spectrum disorder(NMOSD)is an autoimmune demyelinating disease in central nervous system,mainly involving the optic nerves and spinal cord.NMOSD is a relapsing disease with severe residual disability,therefore,prevention of attacks is critical for the preservation of visual and neurologic function.The conventional immunosuppressants,including prednisone,azathioprine,mycophenolate mofetil and methotrexate,can be used to prevent relapse of NMOSD.And immunotherapeutics such as rituximab,tocilizumab and eculizumab are increasingly used in recent years.This review summarizes the current status and the future strategies in treatment of NMOSD based on the progress of NMOSD pathogenesis.

关 键 词：视神经脊髓炎 免疫疗法 水通道蛋白质4 

分 类 号：R744.52[医药卫生—神经病学与精神病学]